Last Updated: July 28, 2026

Litigation Details for US INVENTOR, INC. v. UNITED STATES PATENT AND TRADEMARK OFFICE (D.D.C. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in US INVENTOR, INC. v. UNITED STATES PATENT AND TRADEMARK OFFICE
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Details for US INVENTOR, INC. v. UNITED STATES PATENT AND TRADEMARK OFFICE (D.D.C. 2021)

Date Filed Document No. Description Snippet Link To Document
2021-11-02 21 Memorandum in Support Pharms. Inc. v. Saint Regis Mohawk Tribe, No. 8,629,111 B2, 2018 WL 1100950, at *4 & n.4 (P.T.A.B.…Director, Commissioner for Patents, and Administrative Patent Judges (“Patent Judges”). 35 U.S.C. § 6(c…scope of the patent and interpretation of the individual patent claims.” Id. If a Patent Judge “shares…for the granting and issuing of patents.” 35 U.S.C. § 2(a)(1). The Patent Trial and Appeal Board (“Board…than the patent owner himself—can file a petition to institute inter partes review of a patent.” Arthrex External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document
Error:Operation timed out after 1000 milliseconds with 0 bytes received

Litigation Summary and Analysis of US INVENTOR, INC. v. UNITED STATES PATENT AND TRADEMARK OFFICE | 1:21-cv-02893

Last updated: September 27, 2025


Introduction

The case of US INVENTOR, INC. v. United States Patent and Trademark Office (USPTO), filed in the United States District Court for the District of Columbia, concerns procedural and substantive challenges to USPTO's patent examination and appeals processes. Initiated in 2021 under docket number 1:21-cv-02893, the litigation illustrates ongoing tensions regarding patent law administration, administrative delays, and the scope of procedural remedies available to patent applicants and patent holders.

This analysis dissects the litigation's background, claims, procedural posture, key disputes, and broader implications for patent strategy and USPTO policy.


Case Background

US INVENTOR, INC., a patent holding and licensing entity, filed this lawsuit asserting that USPTO's practices and policies have unlawfully delayed patent ex parte examinations and appeals, violating procedural rights and statutory timelines. The plaintiff claims that these delays, often resulting from administrative backlogs and opaque internal procedures, harm inventors and patent owners by delaying rights enforcement.

The primary legal contention centers on whether USPTO has adhered to statutory deadlines (e.g., 35 U.S.C. § 316(a)) and procedural fairness in managing patent application reviews and appeal processes under the administrative law framework.


Key Claims and Allegations

1. Violation of Statutory Timelines

US INVENTOR alleges that USPTO systematically exceeds the statutory deadlines for patent examination and appeal decisions, leading to undue delays. Specifically, the patent applicant contends that delays in the Patent Trial and Appeal Board (PTAB) decisions undermine the efficiency and predictability of the patent system.

2. Administrative Procedure Violations

The plaintiff asserts USPTO has failed to provide timely and transparent communication regarding application statuses, denying patent owners and applicants fair notice and procedural due process. This includes claims about opaque internal procedures that prolong patent prosecution beyond reasonable limits.

3. Lack of Adequate Remedies

US INVENTOR argues that existing administrative remedies are insufficient or ineffective, and courts should exercise jurisdiction over USPTO’s delays to enforce statutory deadlines. The plaintiff seeks declaratory and injunctive relief compelling USPTO to overhaul its examination and appeal timelines.

4. Constitutional and Due Process Claims

Though less explicit, the complaint hints at potential violations of due process rights under the Fifth Amendment byDelay of patent rights without sufficient administrative recourse, adversely affecting inventors’ ability to enforce rights efficiently.


Procedural Posture

The case was filed in early 2021, with US INVENTOR requesting immediate injunctive relief and a judicial order compelling USPTO to comply with statutory timelines. Key motions have involved motions to dismiss, motions for summary judgment, and requests for expedited proceedings. As of the latest update, the case remains active, with ongoing discovery and briefing.


Legal Disputes and Controversies

1. USPTO’s Administrative Discretion

A core dispute concerns the extent of USPTO’s discretion to delay decisions due to internal backlog or procedural complexity. US INVENTOR argues that statutory deadlines are mandatory and must be enforced, while USPTO contends that administrative discretion allows for delays under the Administrative Procedure Act (APA).

2. Applicability of Judicial Review

The plaintiff seeks judicial review of USPTO’s delays under the APA and patent statutes, challenging the agency’s compliance with statutory timelines and procedural fairness. USPTO maintains that administrative remedies and discretion preclude judicial intervention unless statutory deadlines are clearly violated.

3. Effectiveness of Administrative Remedies

The litigation raises questions about whether the current administrative appeal and review mechanisms sufficiently address delays, or if judicial oversight is necessary to uphold statutory rights.


Implications for Patent Law and Policy

A. Administrative Efficiency and Patent Rights

The case underscores the importance of timely patent examination in fostering innovation, protecting inventors' rights, and maintaining confidence in the patent system. Prolonged delays impair patent enforcement and can stifle innovation.

B. USPTO Reforms

Legal pressures from cases like US INVENTOR may accelerate reforms aimed at reducing examination backlogs, increasing transparency, and clarifying the agency’s authority regarding delays. Possible reforms include boosting examiner staffing, streamlining procedures, and adopting automated case management tools.

C. Judicial Oversight

The case signals a potential shift toward increased judicial oversight of USPTO's administrative delays, especially where delays threaten to violate statutory deadlines or constitutional rights. This could influence USPTO policy and resource allocation.


Key Legal and Business Takeaways

  • Enforceability of Timelines: Patent applicants and holders should vigilantly monitor USPTO deadlines and document delays, potentially seeking judicial intervention if delays are unreasonable.
  • Litigation as a Remedy: The case exemplifies how patent stakeholders can leverage the courts to enforce statutory and procedural rights against administrative delays.
  • Policy Development: Entities involved in patent prosecution must advocate for reforms that prioritize efficiency, transparency, and fair access to review processes.
  • Impact on Innovation Strategies: Extended delays may motivate applicants to pursue alternative IP protections, such as trade secrets, or to expedite filings via prioritized procedures where available.

Conclusion

US INVENTOR, INC. v. USPTO illuminates persistent issues within the U.S. patent system regarding procedural delays and agency accountability. The litigation highlights the tension between administrative discretion and statutory mandates, emphasizing the need for procedural reforms and robust judicial oversight. Stakeholders should anticipate continued legal challenges and policy responses aimed at streamlining patent examination and appeals processes to better serve inventors and patent owners.


Key Takeaways

  • Legal challenges to USPTO delays may catalyze reforms enhancing transparency and timeliness.
  • Patent applicants benefit from vigilant monitoring of application progress and readiness to pursue judicial remedies.
  • The case underscores the critical importance of statutory deadlines in maintaining patentability and enforcement rights.
  • Judicial intervention can serve as a powerful check on administrative delays exceeding statutory bounds.
  • Policy incentives should align to improve USPTO’s operational efficiency, ensuring the patent system remains conducive to innovation.

FAQs

Q1: What are the primary legal issues in US INVENTOR, INC. v. USPTO?
The case centers on alleged delays in patent examination and appeals, statutory deadline violations, and whether USPTO’s administrative discretion justifies these delays, violating patent applicants' rights under law.

Q2: Can courts compel USPTO to speed up patent examinations?
Yes. Courts can enforce statutory deadlines via judicial review under the APA, compelling USPTO to adhere to mandatory timelines, especially if delays violate due process rights.

Q3: How might this case influence future patent administration policies?
It could prompt USPTO to implement systemic reforms, including increasing staffing, enhancing transparency, and clarifying its authority over procedural delays to prevent judicial intervention.

Q4: What remedies are available to patent applicants experiencing delays?
Applicants can file administrative appeals, seek judicial review, and potentially request injunctive relief or declaratory judgments to enforce statutory deadlines and procedural fairness.

Q5: What is the broader significance of this litigation for the patent system?
It symbolizes ongoing efforts to balance administrative discretion with statutory enforcement, aiming to ensure timely patent rights, boost innovation, and uphold procedural justice within the patent ecosystem.


Sources

  1. 35 U.S.C. § 316(a) – Deadlines for patent examination process.
  2. Administrative Procedure Act, 5 U.S.C. § 706 – Judicial review standards.
  3. Court filings and docket information from PACER and court records.
  4. USPTO policies and procedural guidelines (official USPTO publications).
  5. Legal analyses and patent law commentary relevant to administrative delays and judicial oversight.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.